» Articles » PMID: 28416539

Comparison of EUCAST and CLSI Reference Microdilution MICs of Eight Antifungal Compounds for Candida Auris and Associated Tentative Epidemiological Cutoff Values

Overview
Specialty Pharmacology
Date 2017 Apr 19
PMID 28416539
Citations 132
Authors
Affiliations
Soon will be listed here.
Abstract

is an emerging multidrug-resistant yeast. So far, all but two susceptibility testing studies have examined ≤50 isolates, mostly with the CLSI method. We investigated CLSI and EUCAST MICs for 123 isolates and eight antifungals and evaluated various methods for epidemiological cutoff (ECOFF) determinations. MICs (in milligrams per liter) were determined using CLSI method M27-A3, and the EUCAST E.Def 7.3. ANOVA analysis of variance with Bonferroni's multiple-comparison test and Pearson analysis were used on log MICs (significance at values of <0.05). The percent agreement (within ±0 to ±2 2-fold dilutions) between the methods was calculated. ECOFFs were determined visually, statistically (using the ECOFF Finder program and MicDat1.23 software with 95% to 99% endpoints), and via the derivatization method (dECOFFs). The CLSI and EUCAST MIC distributions were wide, with several peaks for all compounds except amphotericin B, suggesting possible acquired resistance. Modal MIC, geometric MIC, MIC, and MIC values were ≤1 2-fold dilutions apart, and no significant differences were found. The quantitative agreement was best for amphotericin B (80%/97% within ±1/±2 dilutions) and lowest for isavuconazole and anidulafungin (58%/76% to 75% within ±1/±2 dilutions). We found that 90.2%/100% of the isolates were amphotericin B susceptible based on CLSI/EUCAST methods, respectively (i.e., with MICs of ≤1 mg/liter), and 100%/97.6% were fluconazole nonsusceptible by CLSI/EUCAST (MICs > 2). The ECOFFs (in milligrams per liter) were similar across the three different methods for itraconazole (ranges for CLSI/EUCAST, 0.25 to 0.5/0.5 to 1), posaconazole (0.125/0.125 to 0.25), amphotericin B (0.25 to 0.5/1 to 2), micafungin (0.25 to 0.5), and anidulafungin (0.25 to 0.5/0.25 to 1). In contrast, the estimated ECOFFs were dependent on the method applied for voriconazole (1 to 32) and isavuconazole (0.125 to 4). CLSI and EUCAST MICs were remarkably similar and confirmed uniform fluconazole resistance and variable acquired resistance to the other agents.

Citing Articles

The multidrug-resistant complex and phylogenetic related species: Insights into antifungal resistance mechanisms.

Ramos L, Barbosa P, Lorentino C, Lima J, Braga A, Lima R Curr Res Microb Sci. 2025; 8:100354.

PMID: 39995443 PMC: 11847750. DOI: 10.1016/j.crmicr.2025.100354.


Molecular characterization of some multidrug resistant Candida Auris in egypt.

Ahmed S, El-Kholy I, El-Mehalawy A, Mahmoud E, Elkady N Sci Rep. 2025; 15(1):4917.

PMID: 39929931 PMC: 11811120. DOI: 10.1038/s41598-025-88656-3.


Cinnamaldehyde nanoemulsion decorated with rhamnolipid for inhibition of methicillin-resistant biofilm formation: and assessment.

Yin L, Guo Y, Xv X, Dai Y, Li L, Sun F Front Microbiol. 2025; 15():1514659.

PMID: 39777149 PMC: 11703839. DOI: 10.3389/fmicb.2024.1514659.


Sphaeropsidin A Loaded in Liposomes to Reduce Its Cytotoxicity and Preserve Antifungal Activity Against .

Buonanno A, Salvatore M, Feola A, Siciliano A, Bellavita R, Imbo L Molecules. 2025; 29(24.

PMID: 39770037 PMC: 11678014. DOI: 10.3390/molecules29245949.


Isolate Specific Transcriptome Changes Exerted by Isavuconazole Treatment in Candida auris.

Balla N, Kovacs F, Toth Z, Harmath A, Bozo A, Majoros L Mycopathologia. 2024; 190(1):5.

PMID: 39729249 DOI: 10.1007/s11046-024-00919-1.


References
1.
Satoh K, Makimura K, Hasumi Y, Nishiyama Y, Uchida K, Yamaguchi H . Candida auris sp. nov., a novel ascomycetous yeast isolated from the external ear canal of an inpatient in a Japanese hospital. Microbiol Immunol. 2009; 53(1):41-4. DOI: 10.1111/j.1348-0421.2008.00083.x. View

2.
Prakash A, Sharma C, Singh A, Kumar Singh P, Kumar A, Hagen F . Evidence of genotypic diversity among Candida auris isolates by multilocus sequence typing, matrix-assisted laser desorption ionization time-of-flight mass spectrometry and amplified fragment length polymorphism. Clin Microbiol Infect. 2015; 22(3):277.e1-9. DOI: 10.1016/j.cmi.2015.10.022. View

3.
Jensen R, Astvad K, Silva L, Sanglard D, Jorgensen R, Nielsen K . Stepwise emergence of azole, echinocandin and amphotericin B multidrug resistance in vivo in Candida albicans orchestrated by multiple genetic alterations. J Antimicrob Chemother. 2015; 70(9):2551-5. PMC: 4553713. DOI: 10.1093/jac/dkv140. View

4.
Arendrup M, Meletiadis J, Mouton J, Guinea J, Cuenca-Estrella M, Lagrou K . EUCAST technical note on isavuconazole breakpoints for Aspergillus, itraconazole breakpoints for Candida and updates for the antifungal susceptibility testing method documents. Clin Microbiol Infect. 2016; 22(6):571.e1-4. DOI: 10.1016/j.cmi.2016.01.017. View

5.
Morio F, Loge C, Besse B, Hennequin C, Le Pape P . Screening for amino acid substitutions in the Candida albicans Erg11 protein of azole-susceptible and azole-resistant clinical isolates: new substitutions and a review of the literature. Diagn Microbiol Infect Dis. 2010; 66(4):373-84. DOI: 10.1016/j.diagmicrobio.2009.11.006. View